953 Indiana Street
About Alector, LLC
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunolgy and human genetics to develop novel therapeutics for Alzheimer’s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector’s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.
30 articles with Alector, LLC
Innovent Biologics Enters into a Collaboration with Alector to Develop and Commercialize Anti-SIRP-alpha Antibody in China
Innovent Biologics, Inc. and Alector, Inc. jointly announced that they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody for the treatment of oncology indications in China.
Cerveau Technologies Inc. today announced a licensing agreement with Alector, in which Cerveau will provide its investigational imaging agent (MK-6240) to Alector for use in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs, made up of aggregated tau protein, are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. A
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INTERCEPT clinical study of AL003.
Here’s a look at some of the biggest U.S. Nasdaq-based initial public offerings in 2019 and some of the more intriguing ones.
Reported results from analysis of the Phase 1b study of AL001 in patients with symptomatic FTD-GRN showing a statistically significant normalization in a number of disease-associated proteins and an initial trend of a decrease compared to baseline levels in plasma Neurofilament
Alector Appoints Dr. Richard Scheller, Lasker Prize Awarded Scientist, and Dr. Thomas Südhof, Nobel Laureate as Co-Chairs of its Strategic Portfolio Advice and Review Committee
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced the appointment of Richard Scheller, Ph.D., and Thomas Südhof, M.D., as co-chairs of the Company’s Strategic Portfolio Advice and Review Committee (SPARC).
Alector Announces Appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as President and Chief Operating Officer
Dr. Suliman will report to Arnon Rosenthal, Ph.D., chief executive officer of Alector.
Alector Announces Phase 1 Data on AL002 at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, reported safety and biomarker data from the single ascending dose phase of the INVOKE Phase1 study of its product candidate, AL002, in healthy volunteers.
Alector, Inc., a clinical stage biotechnology company pioneering immuno-neurology, today announced the initiation of patient screening and enrollment for the INFRONT Phase 2 clinical trial for its product candidate AL001.
Alector, Inc. announced the addition of Kristine Yaffe, M.D., to the Company’s board of directors.
Alector Announces Data from On-going Phase 1b Trial Demonstrating that AL001 Reverses Progranulin Deficiency in Frontotemporal Dementia Patients
Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today reported initial positive data from a subset of patients in the company’s INFRONT clinical study of its product candidate, AL001. AL001 is being evaluated for the treatment of patients with frontotemporal dementia with a granulin mutation (FTD-GRN).
A list of the top 10 biotech IPOs from January to the end of June this year shows significant involvement in the Hong Stock exchange, with five companies based in China, and one, Frontage Holdings, operating in both the U.S. and China.
Winterlight is developing speech-based digital biomarkers to monitor disease progression in patients with FTD in collaboration with Alector
Winterlight Labs Inc, a company that develops speech-based digital biomarkers for neuropsychiatric disorders, announced it is developing vocal biomarkers for monitoring disease progression in frontotemporal dementia patients in collaboration with Alector, a biotechnology company developing therapeutics for neurodegeneration.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first Alzheimer’s disease patient in the Phase 1b portion of the INVOKE clinical study of AL002.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced dosing of the first frontotemporal dementia (FTD) patient in the Phase 1b portion of the INFRONT clinical study of AL001 after successful completion of the healthy volunteer single ascending dose escalation portion of the study.
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Alector, Inc. announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
A summary of IPOs from companies in the biotech and pharma world since January 1, 2019.
Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne
Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the following additions to its board as independent directors: